First American Trust’s Sage Therapeutics SAGE Stock Holding History

First American Trust’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-19,080	Closed	-$1.38M	–	132
2019 Q4	$1.38M	Buy	19,080 +341	+2%	+$41.9K	0.26%	73
2019 Q3	$2.63M	Buy	18,739 +885	+5%	+$148K	0.53%	69
2019 Q2	$3.27M	Buy	17,854 +419	+2%	+$71.5K	0.68%	61
2019 Q1	$2.77M	Buy	17,435 +772	+5%	+$112K	0.61%	62
2018 Q4	$1.6M	Buy	+16,663	New	+$1.91M	0.4%	70

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

First American Trust's SAGE Position: Q1 2020 in Review

First American Trust sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 19,080 shares — an estimated $1.38M sold.

First American Trust first reported a position in SAGE in Q4 2018 and held it in 5 quarters. The position peaked at $3.27M in Q2 2019. 229 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

First American Trust reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
First American Trust sold 19,080 Sage Therapeutics shares in Q1 2020, an estimated $1.38M.
First American Trust first reported a position in Sage Therapeutics in Q4 2018 and held it in 5 quarters.
First American Trust's Sage Therapeutics position peaked at $3.27M in Q2 2019.
229 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on First American Trust's 13F filing for Q1 2020, filed 28 Apr 2020.